RHOFADE Drug Patent Profile

Which patents cover Rhofade, and when can generic versions of Rhofade launch?

Rhofade is a drug marketed by Mayne Pharma and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in thirteen countries.

The generic ingredient in RHOFADE is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Rhofade

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 1, 2031. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for RHOFADE

International Patents:	25
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	55
Clinical Trials:	4
Patent Applications:	2,169
Drug Prices:	Drug price information for RHOFADE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RHOFADE
What excipients (inactive ingredients) are in RHOFADE?	RHOFADE excipients list
DailyMed Link:	RHOFADE at DailyMed

See drug prices for RHOFADE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for RHOFADE

Constraining patent/regulatory exclusivity:

8,883,838

NDA:

208552

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RHOFADE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Actavis Inc.	Phase 3
Teva Pharmaceuticals USA	Phase 3
Candela Corporation	Phase 4

See all RHOFADE clinical trials

Pharmacology for RHOFADE

Drug Class	Vasoconstrictor
Physiological Effect	Increased Sympathetic Activity Vasoconstriction

Paragraph IV (Patent) Challenges for RHOFADE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RHOFADE	Topical Cream	oxymetazoline hydrochloride	1%	208552	1	2019-06-20

US Patents and Regulatory Information for RHOFADE

RHOFADE is protected by seven US patents.

This potential generic entry date is based on patent 8,883,838.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	7,812,049
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	8,883,838		Y
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017		RX	Yes	Yes	12,350,255

Expired US Patents for RHOFADE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017	8,420,688
Mayne Pharma	RHOFADE	oxymetazoline hydrochloride	CREAM;TOPICAL	208552-001	Jan 18, 2017	8,815,929

International Patents for RHOFADE

When does loss-of-exclusivity occur for RHOFADE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

Denmark

European Patent Office

Hong Kong

Japan

Poland

Portugal

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RHOFADE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015274532	Stabilized oxymetazoline formulations and their uses
Canada	2951725	FORMULATIONS D'OXYMETAZOLINE STABILISEES ET LEURS UTILISATIONS (STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES)
European Patent Office	3154517	FORMULATIONS D'OXYMÉTAZOLINE STABILISÉES ET LEURS UTILISATIONS (STABILIZED OXYMETAZOLINE FORMULATIONS AND THEIR USES)

RHOFADE: Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

RHOFADE (oxymetazoline hydrochloride) is a topical prescription vasoconstrictor for facial persistent erythema of rosacea. In market terms, it faces a narrow but persistent demand base tied to rosacea prevalence and adherence-driven repeat purchasing, while branded pricing and payer coverage determine net sales more than pure epidemiology. Financial trajectory is dominated by (1) ongoing reimbursement access for rosacea indications, (2) competitive pressure from other prescription and non-prescription rosacea therapies, and (3) prescription dynamics around formulation-specific outcomes, tolerability, and persistence.

What is RHOFADE’s commercial position in rosacea treatment?

RHOFADE targets facial persistent erythema of rosacea with a topical vasoconstrictor mechanism using oxymetazoline HCl. The commercial attractiveness of the product is shaped by the following market mechanics:

Demand drivers

• Indication specificity. RHOFADE is aligned to persistent erythema, not episodic flushing and not inflammatory lesions. That limits upside versus broad rosacea portfolios but concentrates spend in a defined symptom segment.
• Use frequency and adherence. Topical prescription rosacea therapy creates repeat demand; sales track prescriber adoption, refill behavior, and coverage continuity.
• Outcome expectations. Persistent erythema is highly visible to patients, which increases willingness to pursue ongoing therapy and supports re-purchase if results are maintained.

Pricing and reimbursement dynamics

• Net sales sensitivity to formulary placement. In rosacea, payers typically manage access via tiering and step therapy based on prior topical attempts and cost. Net revenue outcomes therefore hinge on whether RHOFADE stays on preferred or restricted tiers.
• Brand vs generics at the same NDC level. RHOFADE’s topical oxymetazoline HCl status affects competitive benchmarks. If equivalent competitors or alternate branded options proliferate, pricing pressure increases quickly through payer contracts.

Competition map

Rosacea treatment is fragmented across:

• Topical anti-inflammatory agents (e.g., azelaic acid, metronidazole derivatives, ivermectin-class products depending on region and approvals)
• Other prescription vasoconstrictors and symptom-targeted approaches
• Device-based options used intermittently (impacting patient switching)

RHOFADE’s niche keeps it in the “erythema visibility” segment rather than the full rosacea spectrum, so competitors that address broad rosacea phenotypes or multiple symptom domains can divert incremental patients.

How does RHOFADE’s financial trajectory typically evolve in branded topical specialty?

For branded topical prescription products in chronic dermatology, financial trajectory usually reflects a sequence:

1. Penetration phase: initial uptake drives volume growth through formulary access and prescriber education.
2. Maturity phase: growth slows as the addressable “near-term starters” cycle through.
3. Optimization phase: net sales rise or fall primarily via payer contracting, discounting, and patient persistence rather than new prescriber expansion.
4. Competitive shock: new entries, payer policy changes, or substitution dynamics compress pricing or shift channel mix.

RHOFADE’s long-term revenue path follows this pattern, with the most decisive variable being payer access stability for persistent erythema.

What market dynamics drive RHOFADE net sales quarter to quarter?

1) Channel mix: retail vs specialty and copay pressure

Topical dermatology prescriptions often flow through retail and benefit-brokerage channels, but copay design affects:

• time-to-fill
• persistence (early discontinuation from cost)
• payer-driven switching within therapeutic classes

2) Contracting and rebates

Brand dermatology net sales typically track gross-to-net compression from:

• volume-based rebates
• formulary incentives
• chargeback effects tied to wholesaler and payer purchasing patterns

When payers tighten criteria for preferred status, gross sales can be stable while net revenue declines through rebate rate changes.

3) Prescriber behavior and indication labeling discipline

Because RHOFADE is symptom-specific, prescribers shift patients based on phenotype fit. If competing options broaden efficacy claims or show better tolerability for persistent erythema, switching accelerates.

4) Safety/tolerability perceptions and treatment persistence

Topical vasoconstrictors can be sensitive to local tolerability (burning, irritation perceptions), which affects adherence. Even small persistence differences can materially change revenue in chronic symptom treatment.

What is the financial trajectory outlook for RHOFADE?

A practical way to frame trajectory is by “volume vs net price” decomposition. For RHOFADE, the balance typically shifts over time:

• Volume growth tends to be steadier when:
  • it remains preferred for persistent erythema
  • prescribers treat a stable pool of eligible patients
• Net price tends to deteriorate when:
  • payer restrictions intensify
  • competitor contracting improves or introduces formulary alternatives
  • rebate pressure increases to maintain shelf placement

In mature branded dermatology, the most common outcome is:

• slowing revenue growth rather than sharp declines, unless a major payer step policy or substitution event occurs.

Where does RHOFADE sit in patent and lifecycle risk terms?

RHOFADE is a long-lived branded topical product. Lifecycle risk in this space is driven by:

• the strength and clarity of the product’s formulation and use claims
• the probability of generic or authorized alternative entries
• the durability of clinical positioning versus newer branded entries

Patent expiry is only one driver; payer dynamics often change before expiry if competitors gain formulary foothold.

What business implications follow for R&D and investment decisions?

For R&D prioritization

RHOFADE’s commercial durability signals that payers will fund a persistent erythema-targeted topical if:

• outcomes are clinically credible and visible
• tolerability supports persistence
• dosing is simple and patient-friendly

New product strategies should therefore:

• target the erythema phenotype with measurable endpoints
• minimize local tolerability friction
• secure early payer acceptance rather than relying on clinical differentiation alone

For investment and partnering

The key underwriting variable is not only market growth in rosacea, but whether the brand’s net revenue per script holds. Investors should stress test:

• formulary access changes
• rebate pressure
• competitive substitution intensity in retail channel

Key Takeaways

• RHOFADE has a concentrated commercial niche in persistent facial erythema of rosacea, which supports stable demand but limits total market expansion versus broader rosacea portfolios.
• Its financial trajectory in practice is driven by payer access and net pricing as much as by underlying prevalence, because net sales in chronic dermatology are highly rebate and formulary dependent.
• The near-to-mid term outlook is best modeled as mature-brand dynamics: slower growth unless a payer policy shift or competitive substitution materially changes access or persistence.
• For R&D and partnering, the product’s durability implies that payer-ready differentiation and tolerability that supports persistence are decisive.

FAQs

1) What symptom does RHOFADE treat?

RHOFADE treats facial persistent erythema of rosacea via topical oxymetazoline HCl.

2) What drives RHOFADE’s sales more: patient prevalence or reimbursement?

Reimbursement and net contracting typically dominate quarter-to-quarter net sales outcomes, because chronic rosacea prescribing is steady but net revenue is rebate and formulary sensitive.

3) Does competition affect RHOFADE the same way as it affects broad rosacea products?

No. RHOFADE’s symptom-specific positioning reduces the addressable competition set, but competition that improves erythema outcomes or payer coverage can still drive switching.

4) What is the main financial risk profile for branded topical rosacea drugs?

The main risks are gross-to-net compression, payer tier restrictions, and substitution that reduces net revenue per prescription.

5) How should a forecast model RHOFADE?

Use a decomposition that separates script volume (or patient starts and persistence) from net price (rebates, discounts, and formulary mix).

---

References

[1] U.S. Food and Drug Administration. “RHOFADE (oxymetazoline hydrochloride) prescribing information.” FDA label.

DrugChatter Q&A for RHOFADE

Why is rhofade so expensive?
Is there a generic for rhofade?
Rhofade cost without insurance?
Does rhofade have a generic?
Rhofade cost with insurance?